Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1360
Shown on this page
12
Current sort
Recently updated
Campus scope
Penn Medicine (University of Pennsylvania), Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Penn Medicine (University of Pennsylvania), Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 241–252 of 1,360 matching trials with a site at Penn Medicine (University of Pennsylvania), Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support

NCT07048496
Status at this site: Recruiting
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG delivery at home
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Recruiting Phase 2 Interventional

Limited-duration Teclistamab

NCT05932680
Status at this site: Recruiting
View directory record Official record
Conditions
Myeloma Multiple
Interventions
Off Drug Surveillance
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Iowa City, Iowa • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Recruiting No phase listed Observational

Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy

NCT01696721
Status at this site: Recruiting
View directory record Official record
Conditions
Pediatric Patients Treated With Radiation Therapy
Interventions
No intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 21 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
24
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT07412756
Status at this site: Recruiting
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Moorpark, California • Orange, California • New Haven, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Active, not recruiting Not applicable Interventional

Behavioral Economic Approaches for Population-Based Colorectal Cancer Screening

NCT05693649
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Cancer
Interventions
No Direct Patient Outreach, Direct Patient Outreach: Colonoscopy Only, Direct Patient Outreach: Sequential Choice, Visit-Based Nudge/Text, No Nudge/Text
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 72 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109
Site status not listed — check the official record
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions
Denosumab, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma

NCT07082439
Status at this site: Recruiting
View directory record Official record
Conditions
Colorectal Adenocarcinoma Metastatic in the Liver
Interventions
Pembrolizumab, Odetiglucan
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

NCT07069738
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Failure - NYHA II - IV
Interventions
CRT-D with a Quadripolar LV lead, CRT-D with INGEVITY+ pace/sense lead
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Active, not recruiting Phase 3 Interventional

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01863550
Site status not listed — check the official record
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1,087 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2034
U.S. locations
909
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07702578
Site status not listed — check the official record
View directory record Official record
Conditions
AML, MDS
Interventions
TSC-101, Control
Drug · Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
26
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

NCT05473910
Site status not listed — check the official record
View directory record Official record
Conditions
AML, MDS
Interventions
SOC + TSC-101, Control, SOC + TSC-100
Drug · Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT
Recruiting Not applicable Interventional

Ovarian Tissue Transplantation

NCT01870752
Status at this site: Recruiting
View directory record Official record
Conditions
Infertile Females or Females With Ovarian Insufficiency
Interventions
Transplantation of previously cryopreserved ovarian tissu
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 12:00 PM EDT

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists
ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of Pennsylvania at any site, browse by condition, or browse by U.S. city.